The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
4 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $809,962 in first-year total cost, median $199,269.
Most frequent study sections
- Cancer Biomarkers Study Section[CBSS]1
- Clinical Oncology Study Section[CONC]1
- Epidemiology of Cancer Study Section[EPIC]1
- Special Emphasis Panel[ZRG1 PSE-R (90)]1
Most frequent institutions
- JOHNS HOPKINS UNIVERSITY1
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE1
- STATE UNIVERSITY NEW YORK STONY BROOK1
- UNIVERSITY OF ROCHESTER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2015 | Passenger mutations due to activation-induced deaminase as biomarkers in lymphoma1R21CA198072-01 | BURACK, WALTER RICHARD | UNIVERSITY OF ROCHESTER, NY | $214,206 | ZRG1 |
| 2015 | Evaluation of TERT promoter mutations as melanoma biomarkers in tumors and plasma1R21CA198495-01 | POLSKY, DAVID | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $184,331 | CONC |
| 2014 | Plasma and serum biomarkers for Hodgkin lymphoma1R21CA188824-01 | AMBINDER, RICHARD FREDERICK | JOHNS HOPKINS UNIVERSITY, MD | $241,714 | CBSS |
| 2014 | Validating the prognostic value of EGFR768 in neuroblastoma1R21CA187554-01 | CHAN, EDWARD L | STATE UNIVERSITY NEW YORK STONY BROOK, NY | $169,711 | EPIC |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.